Navigation
banner
Together we Drive the Future

Diabetes Summit

2017-03-252017-03-092017-02-09
register 3 for the price of 2 with the coupon code rcdvb!


KEYNOTE SPEAKERS

Alan Cherrington
Professor of Molecular Physiology and Biophysics
Vanderbilt University
Alan Cherrington
Professor of Molecular Physiology and Biophysics
Vanderbilt University
 
About Speaker:

Over the past 44 years Dr. Cherrington has carried out important metabolic research using the conscious dog as a model. During that period he, his colleagues and trainees developed an array of unique surgical approaches (trans-hepatic, renal, gut, head, limb cannulation, 3rd ventricle cannulation, liver and renal denervation, carotid body resection, adrenalectomy, pancreatectomy and duodenal bypass) which when combined with clamping (hormone, metabolite) techniques have allowed the performance of experiments not possible anywhere else in the world. Using the dog, which has high translation value to the human, the Cherrington lab can measure whole body metabolism at the same time as organ balance and molecular signaling (using biopsies). In addition they developed a model of T1DM using alloxan, as well as a model of T2DM using diet manipulation. Using this array of techniques and models the Cherrington lab has assessed the way in which hormones, neural mediators, and metabolites interact to control hepatic glucose production (glycogenolysis/gluconeogenesis) and liver glucose uptake (and storage) in the conscious dog. Their work has resulted in almost 300 peer reviewed papers, as well as 87 review articles. It has been recognized with numerous honors including the Lilly and the Banting Awards for research from the ADA and the Rumbough Award for research from the JDRF.

About twelve years ago Dr. Cherrington decided to devote a significant portion of his research effort to helping expedite drug discovery and device development within the pharmaceutical sector. He set up a structure that provided four opportunities for interaction with pharma and bio-tech partners, 1) consulting, 2) direct help with experiments at a given pharma site, 3) contract research within Vanderbilt and lastly 4) contract research with a 3rd party CRO. This menu of services was based on his many years of experience in the field, as well as the ability to carry out unique proof of concept studies utilizing his conscious dog models. He has now worked with a majority of the major pharmaceutical companies (Merck, Novo Nordisk, Eli Lilly, Sanofi, GlaxoSmithKline, Bristol Myers Squib, Hoffman LaRoche, Biocon, Pfizer, Gilead, Boehringer Ingelheim, Boston Scientific, Abbott, Amylin, Takeda, Tanabe) and many small bio-techs (Abvance, Calibr, Fractyl, Galvani, Metavention, NuSirt, Sensulin, Metabasis, Inhale Therapeutics, Silver Lake, Thermalin, Thetis, VTv Therapeutics, Viacyte, Viking, Zafgen, NGM, OSI). The work performed in Cherrington’s lab was often important in shaping the direction of internal programs and in establishing the credibility of a particular approach both within and without the company. Many of the study outcomes have now been published in peer reviewed journals. Of particular note is the work carried out to investigate novel insulin analogues (Biocon – oral insulin; Novo Nordisk – hepatic-preferential insulin; Eli Lilly – hepatopreferential insulin; Thermalin – ultra rapid insulin; Pfizer – inhaled insulin; Merck – glucose responsive insulin). Likewise, work with GLP-1 (Amylin), incretin mimetics (Amylin) and DPPIV (BMS) inhibitors helped advance that class of compounds. More recently the lab has been working in the electroceutical field (Boston Scientific, Galvani, and Metavention) to establish the feasibility of using nerve stimulation or blockade to alter metabolic regulation in vivo. Finally, it should be noted that Dr. Cherrington’s lab has also carried out studies focused on SGLT-2 inhibitors, 11betaHSD 1 blockers, glucagon receptor antagonists, as well as glucokinase activators. It is worth noting that his collaborations are international, such that he has worked with companies around the world including those based in the USA, Germany, France, Denmark, Japan, Switzerland and India. By offering his expertise and unique models to others he has provided important input into decision making within the pharmaceutical and bio-tech world.


Alexander (Zan) Fleming
President & Chief Exective Officer
Kinexum
Alexander (Zan) Fleming
President & Chief Exective Officer
Kinexum
 
About Speaker:

Dr. Alexander Fleming received his M.D. and internal medicine training from Emory, fellowship training in endocrinology at Vanderbilt and metabolism at National Institutes of Health, where he was a senior fellow. From 1986-98 Dr. Fleming served as reviewer and supervisory medical officer at the US Food and Drug Administration.  He acquired extensive clinical experience and regulatory responsibility in the therapeutic areas of diabetes, other metabolic and endocrine disorders, growth and development, nutrition, lipid-lowering compounds, orphan drug indications, and reproductive indications.  He led reviews of landmark approvals including those of the first statin, insulin analog, metformin, PPAR-agonist, and growth hormone for non-GH deficiency indications. He was responsible for the regulation of the earliest biotech products including human insulin and growth hormone.  He helped to shape a number of FDA policies and practices related to therapeutic review and regulatory communication.

His regulatory and technical expertise has been requested in numerous international settings including the World Health Organization, where he was assigned during 1991-92.  Dr. Fleming was a member of the expert working groups on Good Clinical Practices and General Considerations for Clinical Trials of the International Conference on Harmonization (ICH) and participated on other ICH committees including the Common Technical Document working group. 

He was also the founder and editor in chief of the Virtual Journal of Drug Evaluation, of FDA's Center for Drug Evaluation and Research (CDER), a major contributor to FDA's Good Review Practice (GRP) initiative, and chair of the committee responsible for education and training at CDER.   He conceived and led the first FDA pilot project to utilize the internet for regulatory communication. Dr. Fleming is lead author of the book, “Optimizing Development of Therapies for Diabetes.” He has frequently published scientific articles and book chapters, the most recent chapter, Regulatory Considerations for Early Clinical Development, is in Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development, published by Springer in January 2015.  He has been a member of number corporate and professional society advisory boards.  The most recent is the joint European Association for the Study of Diabetes and American Diabetes Association working group on insulin pump safety. 

Dr. Fleming founded Kinexum, a strategic advisory firm in 2003 and continues to serve as its chief executive officer.


Riccardo Perfetti
Head of Global Medical Team Diabetes, Vice President Global Medical Affairs, Sanofi
Sanofi Diabetes & Cardiovascular Business Unit
Riccardo Perfetti
Head of Global Medical Team Diabetes, Vice President Global Medical Affairs, Sanofi
Sanofi Diabetes & Cardiovascular Business Unit
 
About Speaker:

Riccardo Perfetti, MD, PhD

Head of Global Medical Team Diabetes, Vice President Global Medical Affairs, Sanofi.

Riccardo Perfetti is the Head of Global Medical Team Diabetes, Vice President Global Medical Affairs, Sanofi. He trained as an endocrinologist at La Sapienza University, Rome, where he also achieved a PhD in molecular endocrinology in a joint training program with the Johns Hopkins University. He spent ten years at the National Institutes of Health (NIH), Bethesda, working as a Senior Research Fellow and Senior Staff Scientist. In the following eight years Dr Perfetti held a number of clinical, teaching and research positions at the Cedars-Sinai Medical Center and at University of California Los Angeles, where he directed the clinical diabetes program and the basic science diabetes research laboratory. Prior to joining Sanofi in 2007, he held several positions at Amgen Inc, including Director, Department of Medical Sciences within the Translation Medicine Department and Global Development Lead with the General Medicine Development Department. In his current role, he is responsible for the clinical evidence generation strategy for approved and development programs. Dr Perfetti has published numerous articles and is a reviewer for several journals.


James Tobin
Vice President, Cardiovascular and Metabolism Scientific Innovation
Janssen Research & Development
James Tobin
Vice President, Cardiovascular and Metabolism Scientific Innovation
Janssen Research & Development
 
About Speaker:
GENERAL PLENARY SPEAKERS

John Campbell
Associate Director, Research, Development & Innovation
SNBTS, National Science Laboratory
John Campbell
Associate Director, Research, Development & Innovation
SNBTS, National Science Laboratory
 
About Speaker:

Professor John Campbell is Associate Director of Research and Development at the Scottish National Blood Transfusion Service (SNBTS) in Edinburgh. He completed his PhD in Pathology at Edinburgh in 1995 on the immunopathogenesis of lymproliferative disease, and has worked in the cellular therapy field for over 20 years in academic and industry positions. He is currently the national head of research for SNBTS and holds academic appointments at the Universities of Glasgow and Edinburgh. SNBTS has a substantial cellular therapy research programme, with over 40 full time scientists working on basic cellular function; translation of laboratory protocols to full GMP processes; and production of cellular therapeutics for treatment of patients. SNBTS has a dedicated, fully MHRA licensed, GMP cellular therapy production centre at the Scottish Centre for Regenerative Medicine. This GMP manufacturing and development capacity will be substantially increased when SNBTS moves to the Jack Copland Centre, Edinburgh, in early 2017. Cellular therapeutics in development and early phase clinical trials include, mesenchymal stromal cells, corneal limbal stem cells, macrophages for tissue repair and virus -specific T Lymphocytes.


Douglas Losordo
Chief Medical Officer, Senior Vice President of Clinical, Medical & Regulatory Affairs
Caladrius Biosciences
Douglas Losordo
Chief Medical Officer, Senior Vice President of Clinical, Medical & Regulatory Affairs
Caladrius Biosciences
 
About Speaker:

Dr. Losordo is the Chief Medical Officer and Senior Vice President of Clinical, Medical and Regulatory Affairs of Caladrius Biosciences, Inc, Clinical Professor of Medicine at  the New York University Langone Medical Center  and Adjunct Professor of Medicine at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.

Dr. Losordo’s career has been dedicated to patient care and to the development of novel therapeutics aimed at the reversal or repair of chronic conditions such as heart failure, critical limb ischemia, cancer and diabetes.

A native of Brooklyn, NY, he received his medical degree from the University of Vermont. Dr. Losordo completed an internship, residency and fellowship at St. Elizabeth’s Medical, Boston, Massachusetts, where he subsequently joined the faculty, working with the late Jeff Isner to develop a program in gene therapy and cell-based tissue repair. Dr. Losordo’s group has executed the full “translational medicine” paradigm: identifying potential therapeutic approaches in the laboratory, investigating these strategies in pre-clinical/IND-enabling models and designing and executing first-in-human and proof-of-concept clinical trials as the study sponsor/IND-holder. His work has included developing VEGF gene therapy for myocardial ischemia and diabetic neuropathy, CD34+ cell therapy for refractory angina, critical limb ischemia, severe claudication and coronary microvascular dysfunction and regulatory T cell therapy for autoimmune disease. Two of these candidates advanced to phase 3. At Caladrius Dr. Losordo has initiated a phase 2 study of autologous regulatory T cell therapy for new onset type 1 diabetes in children and recently received Japanese PMDA agreement on a study of CD34 cell therapy for critical limb ischemia targeting conditional approval under the new Japanese regulatory rules governing regenerative therapies. In addition to his own work Dr. Losordo has also mentored numerous scientists and physician-scientists from around the world who now have their own independent programs in translational research.


Felicia Pagliuca
Vice President, Cell Biology R&D
Semma Therapeutics
Felicia Pagliuca
Vice President, Cell Biology R&D
Semma Therapeutics
 
About Speaker:

Dr. Pagliuca currently serves as Vice President of Cell Biology Research and Development and is scientific co-founder of Semma Therapeutics. She leads cell-based research and development and plays a key role in supporting Semma's preclinical, regulatory, and manufacturing strategies for its cell therapy products. Felicia also works closely with Semma’s senior leadership on corporate development activities, including key collaborations and partnerships. Previously, Felicia was a postdoctoral fellow in Professor Doug Melton’s laboratory at the Harvard Stem Cell Institute. Felicia was part of the team in the Melton lab that discovered how to generate stem cell derived beta cells and published a seminal paper in Cell in 2014. She is an expert in stem cell biology and diabetes and one of the inventors of Semma Therapeutics’ key technologies. Felicia received a B.S. from Duke University and a Ph.D. from Cambridge University where she was a Marshall Scholar. She is currently on leave from Harvard Business School where she was a Kaplan Fellow.


Mark Zimmerman
Vice President, Strategy and Business Development
ViaCyte
Mark Zimmerman
Vice President, Strategy and Business Development
ViaCyte
 
About Speaker:

Mark Zimmerman received his bachelors in Biology from Syracuse University and his masters and doctorate in Biomedical Engineering from Rutgers University. Mark joined UMD-New Jersey Medical School as an Assistant Professor in 1986 and left in 1996 as an Associate Professor of Surgery with tenure. His research interests spanned musculoskeletal tissue engineering, sports medicine, trauma, and spine biomechanics and biomaterials.

Mark joined Johnson and Johnson in 1997 as a principal scientist/group leader and transitioned into regenerative medicine projects related to orthopaedic surgery, wound healing, vascular biology, and diabetes. Mark was appointed executive director of a Lifescan incubator, BetaLogics, in July 2002. BetaLogics transitioned to a Johnson and Johnson Internal Venture in 2004. The mission of BetaLogics was to discover and develop a cellular product to treat diabetes. Mark was appointed Venture Leader/Vice President of BetaLogics, a business unit of Janssen R&D LLC in 2009. Janssen completed a business transaction with ViaCyte in 2015 and merged the assets of BetaLogics into ViaCyte. Mark is currently seconded to ViaCyte and serves as the Vice President of Strategy and Business Development.

Diabetes Drug Discovery & Development
DISTINGUISHED SPEAKERS

Raja-Elie Abdulnour
Instructor of Medicine
Brigham and Women's Hospital
Raja-Elie Abdulnour
Instructor of Medicine
Brigham and Women's Hospital
 
About Speaker:

Raja-Elie Abdulnour is a physician-scientist faculty member at Harvard Medical School and the Pulmonary and Critical Care Division of the Brigham and Women's Hospital. His research interests are centered on essential fatty acid-derived Specialized Pro-resolving Mediators (SPM) and their role in host defense and resolution of inflammation. He is an investigator in a NIH-funded program project grant led by Prof Charles Serhan that aims to harness SPMs and the recently discovered bioactive SPM-sulfido conjugates for resolution pharmacology. The over-arching goal is to develop novel therapies to better treat human diseases defined by uncontrolled inflammation and impaired tissue repair, such as diabetes mellitus.


William Bachovchin
Professor, Department of Biochemistry
Tufts University School of Medicine
William Bachovchin
Professor, Department of Biochemistry
Tufts University School of Medicine
 
About Speaker:

Dr. Bachovchin serves as Executive Vice President and Chief Scientist and member of the board of directors of Arisaph pharmaceuticals since he co-founded the company in 1999. He was also a co-founder of Point Therapeutics which was a publically traded biotechnology company prior to its merger with Dara BioSciences. Dr. Bachovchin is also Professor of Biochemistry at Tufts University School of Medicine.

Dr Bachovchin received a BS degree in Biology from Wake Forest University a doctoral degree in Chemistry from The California Institute of Technology, and did postdoctoral work at Harvard Medical School before arriving at Tufts. Dr. Bachovchin is an author on more than 100 peer reviewed journal articles, and an inventor on more than 30 issued patents as well as numerous pending applications. Dr. Bachovchin is a leader in the areas of NMR spectroscopy, enzymes mechanisms and drug design and discovery, especially in areas pertaining to the post proline cleaving family of enzymes. To date three drugs designed by Dr. Bachovchin have entered human clinical trials and several more are in late stage preclinical testing.


Robin Barbour
Senior Director Antibody and Assay Development
Prothena Biosciences Inc.
Robin Barbour
Senior Director Antibody and Assay Development
Prothena Biosciences Inc.
 
About Speaker:

Robin has over 25 years of experience developing antibodies for both misfolded proteins and cell adhesion molecules. Currently two of these mAbs are in clinical trials, NEOD001 for AL amyloidosis and PRX002 for Parkinson’s Disease. Previously at Elan, her group developed the murine version of Tysabri for Multiple Sclerosis, and Bapineuzumab for Alzheimers. In addition to antibody development, Robin’s group is responsible for the development of assays to support clinical trials including pK, ADA, Biomarker and cell based potency assays.


Sudha Biddinger
Associate Professor of Pediatrics
Children's Hospital of Boston
Sudha Biddinger
Associate Professor of Pediatrics
Children's Hospital of Boston
 
About Speaker:

Dr. Biddinger is an Associate Professor of Pediatrics at Boston Children’s Hospital/Harvard Medical School.  Her lab is focused on identifying novel targets of insulin that are relevant to the development of dyslipidemia, atherosclerosis and fatty liver disease in the insulin resistant states of obesity and diabetes. 

Dr. Biddinger performed her undergraduate studies at Princeton University and obtained her MD/PhD from the Johns Hopkins School of Medicine.  She completed her internship, pediatrics residency, and fellowship in pediatric endocrinology at Boston Children’s Hospital. 


Bruno Doiron
Faculty Member, Medicine - Diabetes Division
University of Texas Health Science Center at San Antonio
Bruno Doiron
Faculty Member, Medicine - Diabetes Division
University of Texas Health Science Center at San Antonio
 
About Speaker:

Bruno Doiron, Ph.D is a faculty member at the University of Texas Health Science at San Antonio. He received his undergraduate degree from University of Moncton, N.B. Canada and graduate degrees from University of Montreal, QC, Canada and University of Paris Descartes, Paris, France. As project leader he has made major discoveries in the field of gene regulation by nutrients and has 4 patents on the modulation of glucose metabolism as it relates to the treatment diabetes and cancer. Dr. Doiron has extensive experience in basic research at the physiologic and molecular levels and in respective applications to the biotechnology field.    


Denise Faustman
Director of the Immunobiology Laboratory at the Massachusetts General Hospital (MGH)
Associate Professor of Medicine at Harvard Medical School
Denise Faustman
Director of the Immunobiology Laboratory at the Massachusetts General Hospital (MGH)
Associate Professor of Medicine at Harvard Medical School
 
About Speaker:

Denise Faustman, MD, PhD, is Director of the Immunobiology Laboratory at the Massachusetts General Hospital (MGH) and an Associate Professor of Medicine at Harvard Medical School. She is currently leading a clinical trial program investigating the potential of the BCG vaccine as a disease reversal treatment for long-standing type 1 diabetes. Her research accomplishments include the first scientific description of modifying donor tissue antigens to change their foreignness, the identification of interrupted T cell education through MHC class I, and the identification of autoimmune T cell sensitivity to TNF. For both autoreactive CD8 T cells she has identified the TNFR2 receptor as central and also the TNFR2 receptor for the expansion of beneficial Treg cells.  These achievements have earned her awards including the National Institutes of Health and National Library of Medicine “Changing the Face of Medicine” Award as one of 300 American physicians (one of 35 in research) honored for seminal scientific achievements in the United States, the Oprah Achievement Award for “Top Health Breakthrough by a Female Scientist,” and the Women in Science Award from the American Medical Women’s Association and Wyeth Pharmaceutical Company.  Dr. Faustman’s research has been highlighted in publications including Science, Nature, The Wall Street Journal, The New York Times, Los Angeles Times, The London Financial Times and Scientific American. She earned her MD and PhD from Washington University School of Medicine, in St. Louis, Missouri, and completed her internship, residency, and fellowships in Internal Medicine and Endocrinology at the Massachusetts General Hospital.

 

Judith Gorski
Global Director, Scientific Engagement
Crown Bioscience Inc.
Judith Gorski
Global Director, Scientific Engagement
Crown Bioscience Inc.
 
About Speaker:

Dr. Judith Gorski is Global Director of Scientific Engagement at Crown Bioscience Inc., and is a pharmacologist with over 18 years of experience in drug discovery and development in a large pharmaceutical environment.  She has extensive experience in basic research and targeted drug discovery in the disease areas of type 1 and 2 diabetes, dyslipidemia, atherosclerosis, obesity, and metabolic syndrome.  Dr. Gorski has co-authored publications in Nature, Obesity, Obesity Research, Cell Metabolism, Journal of Lipid Metabolism.

Prior to joining CrownBio, Dr. Gorski’s work at Merck focused on target identification/validation and small molecule and biologics identification/optimization with the aim of recommending lead candidates for clinical development. Her primary responsibilities were to establish and validate appropriate primary, secondary and tertiary in vivo models of dyslipidemia, obesity, metabolic syndrome, and type 1 and 2 diabetes. In addition to preclinical work, Dr. Gorski has been a member of early development teams to move lead candidates into development and has collaborated across an array of disciplines, including drug safety and metabolism, pharmaceutical sciences, early clinical development, medical affairs, regulatory affairs, and commercial development.

Dr. Gorski received her Ph.D. in Neuroscience from University of Medicine and Dentistry, New Jersey.


Steven Shoelson
Professor, Department of Biological Chemistry & Molecular Pharmacology
Joslin Diabetes Center
Steven Shoelson
Professor, Department of Biological Chemistry & Molecular Pharmacology
Joslin Diabetes Center
 
About Speaker:

Larry Steinman
Professor, Pediatrics and Neurology
Stanford University
Larry Steinman
Professor, Pediatrics and Neurology
Stanford University
 
About Speaker:

Steinman is Professor of Neurology, Neurological Sciences and Pediatrics at Stanford University and Chair of the Stanford Program in Immunology from 2001 to 2011. His research focuses on what provokes relapses and remissions in multiple sclerosis (MS) and in neuromyelitis optica (NMO) and the quest for antigen specific therapy. He and colleagues have advanced an antigen specific therapy in type 1 diabetes to Phase 2b.  He is also developing a small molecule therapeutic in trials for Huntington’s Disease. Steinman identified guardian molecules in brain that have protective properties in a number of inflammatory conditions.  These protective molecules activate regulatory B cells. 

Steinman was senior author on the 1992 Nature article that led to the drug Tysabri, approved for MS and Crohn’s disease.

Dr. Steinman graduated from Dartmouth College, Magna Cum Laude in Physics. His MD is from Harvard Medical School.  He was a post-doctoral fellow in chemical immunology fellow at the Weizmann Institute of Science. After neurology residency he remained on the faculty in 1980.  He has received numerous honors, including the John M. Dystel Prize in 2004, the Javits Neuroscience Investigator Award from the NINDS twice, the Charcot Prize in MS research, and the Cerami Prize in Translational Medicine. Steinman is a member of the National Academy of Sciences, and the National Academy of Medicine.


Pragalath Sundararajan
Scientist
BERG Health
Pragalath Sundararajan
Scientist
BERG Health
 
About Speaker:

Pragalath Sundararajan works as a Scientist in the Endocrinology program at BERG. He received his Bachelor of Technology in Biotechnology from Anna University, India and MS in Biotechnology from Northeastern University.

Pragalath began his career at BERG five years ago and has worked on the validation of Diabetes drug targets identified by BERG’s proprietary Interrogative Biology® Platform. His work has contributed to BERG’s therapeutic pipeline which currently has multiple novel anti-diabetic biologic molecules that have progressed beyond the proof of concept phase and are in various stages of pre-clinical development. His current research efforts are focused on supporting the pre-clinical development of these molecules and in the identification of novel drug targets for Diabetes and other metabolic diseases.

Diabetes Partnering & Deal-Making
DISTINGUISHED SPEAKERS

Mostafa Analoui
Executive Director
UCONN Ventures
Mostafa Analoui
Executive Director
UCONN Ventures
 
About Speaker:

Mostafa Analoui, Ph.D., is Executive Director of UCONN Ventures. Previously, he was Head of Healthcare and Life Sciences at Livingston Securities (New York, NY) with investment focus in private and public companies in biotech, medtech and healthcare services. Prior to that he was the Senior Director at Pfizer Global Research and Development. Dr. Analoui is actively involved in investment, management and scientific/business development of nanotechnology, drug discovery/development, diagnostic imaging, and global strategies.

While at Pfizer, he was the Site Head for Global Clinical Technology in Groton and New London, a division focusing on emerging technologies for development and validation of biomarkers and diagnostics for drug development. Prior to joining Pfizer, Dr. Analoui was the Director of Oral and Maxillofacial Imaging Research, Associate Professor of Radiology at Indiana University, and Associate Professor of Biomedical Engineering and Electrical & Comp Engineering at Purdue University. He was also President and CEO of Therametric Technology Inc. He has received his Ph.D. from Purdue University, followed by Post-Doctoral Fellowship at IBM TJ Watson Research Center in NY.

In addition to industry leadership in biomedical and technology fields, he consults and lectures in US, Europe and Asia. He has also served on various scientific, regulatory, and business advisory committees and boards, including NIH, NSF, PhRMA, NASA, and OECD. Dr. Analoui has authored over 130 publications, including journal articles, book chapters and technical reports.  Dr. Analoui is currently Adjust Professor at Brown University (Providence, RI), Northeastern University (Boston, MA) and University of Connecticut (Storrs, CT). He is also senior member of IEEE, SPIE, and RSNA.

He was Chairman of the Board of VirtualScopics (Nasdaq: VSCP) and currently serves as board member of Calando Pharmaceutical (Nasdaq: ARWR), BEACON (Biomedical Engineering Alliance and Consortium) and NanoBusiness Commercialization Association.


Jonathan Behr
Managing Director
JDFR
Jonathan Behr
Managing Director
JDFR
 
About Speaker:

Jon joined the T1D Fund from Partners Healthcare Innovation, where he was a Market Sector Leader and Executive in Residence, driving technology translation from research hospitals affiliated with Harvard Medical School. He previously held senior venture creation roles including Vice President of New Ventures for Enlight Biosciences and Principal at PureTech Ventures (LON:PRTC). Jon has co-founded and supported seven companies (including holding C-level operating, business development and board director positions) and managed alliances with top pharmaceutical companies. He earned his Ph.D. at Massachusetts Institute of Technology as a Howard Hughes fellow and his B.S. from Rice University.


Richard Berenson
Chief Executive Officer
Thermalin Diabetes
Richard Berenson
Chief Executive Officer
Thermalin Diabetes
 
About Speaker:

Rick is a serial entrepreneur who has successfully launched and financed multiple life science and other organizations around important new technologies in complex markets. A former McKinsey & Company consultant, Rick received a JD-MBA from Harvard Business and Law Schools in 1984 and is a graduate of Harvard College.


Brian Bloomquist
Senior Director, Global External Research and Development
Eli Lilly
Brian Bloomquist
Senior Director, Global External Research and Development
Eli Lilly
 
About Speaker:

Brian has been at Eli Lilly since April 2006 where his role within the Diabetes External Innovation group is to lead the evaluation of external partnering opportunities in diabetes and endocrine disease for technical merit and portfolio fit.  Prior to coming to Lilly, he spent 11 years in the Metabolic Disorders group at Bayer Pharmaceuticals where his laboratory was engaged in obesity drug discovery and he held multiple leadership positions in the management of the Obesity Research portfolio.  Brian completed his post-doctoral studies at The Johns Hopkins University School of Medicine where he studied dopaminergic signaling in the laboratory of Dr. Betty Eipper following his graduate studies at Purdue University where he investigated Drosophila photoreceptor signal transduction under Dr. William Pak and his thesis was awarded the first A.H. Ismail Interdisciplinary Dissertation Award.  Dr. Bloomquist has been a speaker or panelist at multiple conferences including Bio-Europe, GTC Bio, Mass Bio, Ausbiotech, and the Queensland Investment Forum, has been cited in Close Concerns, a leading diabetes and obesity healthcare information company, is an inventor on a number of patents, and is the author of multiple peer-reviewed publications, including an article highlighted on the cover of the journal Cell. 


Laura Brandner
Manager of Global Software Innovation
Abbott
Laura Brandner
Manager of Global Software Innovation
Abbott
 
About Speaker:

Laura Brandner manages Product Management for Digital Platforms at Abbott Diabetes Care.

Laura has a Bachelor of Science in Chemical Engineering from Purdue University and a Master’s in Business Administration from the Haas School of Business at UC Berkeley.

She began her career at Abbott and has spent time in various Abbott divisions working in engineering, project management, planning and forecasting, innovation, and now software product management.

In her current role, she manages innovative software products from ideation to launch including product design and definition, positioning/branding, customer service, legal, data privacy, regulatory, quality, and product lifecycle management.


John Brooks
Managing Director
Healthcare Capital LLC
John Brooks
Managing Director
Healthcare Capital LLC
 
About Speaker:

John L. Brooks III is the Managing Director of Healthcare Capital LLC, which advises early-stage life sciences companies. Healthcare Capital specializes in advancing disruptive and innovative solutions in healthcare, especially in obesity, pre-diabetes, and diabetes. Mr. Brooks is on the board of a number of for-profit and not-for-profit organizations.

Mr. Brooks is the former President and Chief Executive Officer of the Joslin Diabetes Center, a Boston based diabetes research, clinical care, and education organization.

Mr. Brooks is a well-known life sciences executive. He has co-founded seven life sciences companies, including Insulet (PODD), a disruptive insulin delivery company. He was a co-founder of Prism Venture Partners, a $1.25B venture capital firm.

Prior to that, Mr. Brooks was a senior medical device executive at Pfizer, and a senior manager at Arthur Andersen & Co. in Boston, MA, where he focused on early stage companies.

A native of Massachusetts, he holds an M.S. in Business Administration and a B.B.A. cum laude from the University of Massachusetts at Amherst and he is a Certified Public Accountant.


MaryJulia Brosnan
Director, External Collaborations and Scientific Alliances
Pfizer
MaryJulia Brosnan
Director, External Collaborations and Scientific Alliances
Pfizer
 
About Speaker:

Victor Chapela
Chief Executive Officer and Co-Founder
Suggestic
Victor Chapela
Chief Executive Officer and Co-Founder
Suggestic
 
About Speaker:

Benjamin Conway
Managing Director, Life Sciences
Consilium Partners
Benjamin Conway
Managing Director, Life Sciences
Consilium Partners
 
About Speaker:

Benjamin Conway is a managing director and head of the life sciences group for the Boston-based investment bank Consilium Partners.   Ben has over 20 years' experience in life science banking, with transaction experience in the biopharma and specialty pharma, medical device and diagnostics sectors as well as the ancillary service sectors.  Prior to joining Consilium, he was managing director of Johnston Blakely & Company, a boutique life science investment bank he founded in 2002 and subsequently acquired by the CMC Consulting Group AG.  Previously, Ben was group head of biotechnology investment banking at Adams, Harkness & Hill (today Canaccord Genuity), where he led the Adams, Harkness group to a top ranking for completed middle market M&A transactions.  Ben's experience also includes positions with Abbott Laboratories and Bain & Company. 


Shantanu Gaur
Co-Founder & Chief Scientific Officer
Allurion Technologies
Shantanu Gaur
Co-Founder & Chief Scientific Officer
Allurion Technologies
 
About Speaker:

Robert Geho
Co-Founder and Chief Executive Officer
Diasome Pharmaceuticals Inc
Robert Geho
Co-Founder and Chief Executive Officer
Diasome Pharmaceuticals Inc
 
About Speaker:

Robert Geho is co-founder and CEO of Diasome Pharmaceuticals, Inc., a privately-held developer of liver targeting systems for insulin and other drugs to treat diabetes.  Working alongside a team of nanotechnology formulation and protein chemistry experts, highly experienced clinical research professionals, and globally recognized investors, Robert is actively involved in the clinical development of Diasome’s Hepatocyte Directed Vesicle “HDV”) system.  HDV Insulin is Phase 3-enabled and is currently being tested in a multi-center Phase 2b study in patients with Type 1 diabetes.


Karin Hehenberger
Chief Executive Officer & Founder
LyfeBulb
Karin Hehenberger
Chief Executive Officer & Founder
LyfeBulb
 
About Speaker:

Dr. Karin Hehenberger is an experienced life sciences executive, who has dedicated her career to applying medical science to impacting people living with chronic disease. Dr Hehenberger founded and launched Lyfebulb in January of 2014, after close to 20 years of experience in the healthcare industry, which she entered after obtaining M.D. and Ph.D. degrees from the Karolinska Institute in Stockholm, Sweden and conducting her post-doctoral work as a JDRF fellow at the Joslin Diabetes Center at Harvard Medical School. Lyfebulb is a company focused on bringing innovative and impactful biopharmaceutical, medical device and consumer products to market. The overall Mission is to improve the quality of life for people living with chronic disease, with a special focus on investing in diabetes innovation leveraging the lived experience by patient entrepreneurs. Dr Hehenberger has held leadership positions in the biopharmaceutical industry including at Johnson & Johnson, Eyetech pharmaceuticals and Coronado biosciences, as well as on the investment side of healthcare at both private and public multi-billion dollar funds. Dr Hehenberger is considered an expert in the field of Metabolic disease and is an invited speaker at numerous conferences and at corporate strategy sessions on this topic, as well as the subject of patient impact, innovation and alternative financing methods for early stage research. She recently gave a TEDX talk in Lugano, Switzerland on the importance of patient involvement in reversing the global diabetes pandemic. She is a Senior Advisor, Biotechnology and Medical Innovation for the Department of Endocrinology and Surgery at the Karolinska Institute, the Scientific Advisor to the CEO of Helsinn, and sits on the US corporate board for Orgenesis (ORGS), the advisory boards for DietSensor and Diasome. She is also a board member of the Rolf Luft Diabetes Research Foundation and was previously a board member of the Lighthouse Guild foundation. Dr Hehenberger has published a book called “The Everything you need to know about diabetes cookbook”. She is a Swedish citizen, but based in New York City.


Nathaniel Heintzman
Director, Partner Portfolio
Dexcom
Nathaniel Heintzman
Director, Partner Portfolio
Dexcom
 
About Speaker:

Nathaniel Heintzman is the Senior Manager of Data Partnerships at Dexcom Inc, where he leads efforts to support and expand the diabetes innovation ecosystem. Prior to joining Dexcom in early 2014, he directed the Diabetes Informatics + Analytics Lab (DIAL) at the University of California, San Diego (UCSD), where he served as faculty in the School of Medicine’s Division of Biomedical Informatics. Heintzman also has a long history of diabetes advocacy, including his founding role in Insulindependence and volunteering for other diabetes advocacy organizations.

Heintzman received his PhD in Biomedical Science from UCSD and his BA in Biochemistry and Molecular Genetics at Gustavus Adolphus College (St Peter, Minn), and his graduate and postdoctoral research in genomics and bioinformatics was published in Nature. He lives in San Diego, California with his wife, and enjoys spending his spare time surfing, playing bass and keyboard in his rock cover band, and gardening.


Scott Johnson
Communications Lead
mySugr GmbH
Scott Johnson
Communications Lead
mySugr GmbH
 
About Speaker:

Scott is an experienced patient advocate. He works with a wide range of stakeholders across the healthcare environment to help them establish effective communication with the patient community. His expertise in the diabetes social media space is recognized worldwide and he advises organizations within the healthcare, food, and consumer goods industries.

Today he is Communications Lead, USA for mySugr and Patient Pathways Lead in the Diabetes Division of Delta Project Management. He manages a long-standing and award-winning blog “Scott's Diabetes” that reaches hundreds of thousands of people annually.

Scott is also a member of the Children with Diabetes faculty where he develops educational curriculums and content for the Friends for Life annual conference and regional events. He is on the Executive Committee of the Board of Directors for the Diabetes Hands Foundation, the Board of Directors for the Diabetes Community Advocacy Foundation, and is a founding member of Partnering for Diabetes Change, a coalition of people living with diabetes and industry representatives working to support underserved communities. He is interested in how these types of interactions including peer-to-peer support impact patient outcomes and routinely presents his work.


Charles O'Connell
Founder and CEO
Fitscript
Charles O'Connell
Founder and CEO
Fitscript
 
About Speaker:

Charlie is the Founder and CEO of Fitscript, a company dedicated to helping people living with diabetes through exercise, education and technology. Fitscript’s GLUCOSEZONE program is a digital health solution that provides exercise guidance based on real-time glucose levels, captured from wearable devices and glucometers. The GLUCOSEZONE program provides real-time and algorithmic based guidance, access to CDE's and digital health coaches, and offers live stream programming as well as programming for at home, gym, or outside; on the end users digital platform of choice. To date, over 400,000 people around the globe have benefited from GLUCOSEZONE digital programming.

Recognizing a lack of guidance and support related to exercise and diabetes, Charlie founded FITSCRIPT.COM in September of 2012 to help others with diabetes reach their fitness goals through structured exercise guidance, support, and training. In the fall of 2013, Charlie opened the FITSCRIPT Diabetes Training Center, the world’s first exercise clinic dedicated exclusively to diabetes prevention and management.

Diagnosed with Type 1 diabetes at Yale New Haven Hospital in the fall of 1996, Charlie is a graduate of the University of Pennsylvania (’02) where he was a two-sport varsity athlete (Football and Track and Field), as well as high school All-American in Track and Field. Before founding FITSCRIPT, Charlie worked in business development for a successful start-up software company.


Nandan Padukone
Senior Vice President, Innovation
Joslin Diabetes Center
Nandan Padukone
Senior Vice President, Innovation
Joslin Diabetes Center
 
About Speaker:

Dr. Nandan Padukone heads up Joslin Innovation as Senior Vice President and Global Head, which he helped launch as a business center of Joslin Diabetes Center to create strategic relationships with industry, governments and healthcare providers to leverage Joslin’s world-leading expertise in diabetes-directed research, education and clinical care. His research interests include redesigning health care delivery models to optimize outcomes for people with diabetes. He has created more than 25 strategic alliances with pharmaceutical, biotechnology, device and care delivery organizations at the Joslin Diabetes Center in less than 4 years.

Dr. Padukone has 17 years in biotechnology management and entrepreneurial ventures involving diagnostics (Nuvera), therapeutics (Altus Pharma), bioinformatics (Silico Insights), and renewable energy (NREL). He helped launch Nuvera Biosciences as founding CEO in 2005, a venture focused on cancer therapy and pharmacogenomics, in collaboration with MD Anderson Cancer Center. At Nuvera, he was responsible for venture capitalization, product validation, and business development, and forged alliances with cancer centers and diagnostic companies in US and Europe. He actively engaged with regulatory agencies, healthcare organizations, and patient advocacy groups. 

Previously, Dr. Padukone was the founder and CEO of Silico Insights, a bioinformatics company launched in 2000, and served previously as Director of Technology and Board Member at Altus Biologics, a spin-out venture of Vertex Pharmaceuticals. He also led scientific teams at the National Renewable Energy Laboratory (NREL) and led industrial partnerships in development of bioethanol and biodegradable polymers.

Dr. Padukone holds a Ph.D. in Biotechnology and Biochemical Engineering from North Carolina State University, an MBA from University of Denver, MS from SUNY Buffalo, and a B. Tech. from IIT, Mumbai, India.


Steven Russell
Assistant Professor of Medicine
Massachusetts General Hospital
Steven Russell
Assistant Professor of Medicine
Massachusetts General Hospital
 
About Speaker:

Aaron Schwartz
Director, R&D Innovation Sourcing
Novo Nordisk Inc.
Aaron Schwartz
Director, R&D Innovation Sourcing
Novo Nordisk Inc.
 
About Speaker:

Aaron is a Director in Novo Nordisk’s R&D Innovation Sourcing team.  In this capacity, Aaron is responsible for the search an evaluation of new therapeutics and enabling technologies for protein, peptide, and antibody drugs.  Prior to joining Novo Nordisk, Aaron worked in the MIT Technology Licensing Office for 13.5 years.  During this time, he worked on license and sponsored research agreements with life sciences companies from startups to big biotech/pharma and everything in between.  He also managed a portfolio of over 650 technologies.  Before Aaron’s time at MIT, he was a management consultant to big pharma and a startup.  Aaron has an undergrad degree in biology from the University of Chicago and a Masters degree in biology from MIT.


Omid Veiseh
Founding Scientist and Head of Innovation
Sigilon
Omid Veiseh
Founding Scientist and Head of Innovation
Sigilon
 
About Speaker:

Dr. Omid Veiseh is the Founding Scientist and Head of Innovation at Sigilon. He also holds academic position as an Assistant Professor and CPRIT Scholar in Cancer Research in Department of Bioengineering at Rice University. Dr. Veiseh has over a decade of experience developing biotechnologies for clinical application. He received a dual Ph.D. in Materials Science, Engineering and Nanotechnology from the University of Washington. He completed his postdoctoral research with Prof. Robert Langer and Prof. Daniel Anderson at Koch Institute for Integrative Cancer Research at MIT and Harvard Medical School. Over the course of his career he has authored, or co-authored more than 50 peer-reviewed publications including those in Nature, Nature Biotechnology, Nature Materials, Nature Medicine, Nature Reviews Drug Discovery, and is an inventor on 20 pending or awarded patents, many of which have been licensed for commercialization by 3 separate biotechnology companies. He has received numerous awards and fellowships including: NSF Integrative Graduate Education and Research Training (IGERT) Fellowship, NIH T32 Ruth L. Kirschstein National Research Service Award Postdoctoral Fellowship, Juvenile Diabetes Research Foundation Postdoctoral Fellowship, DOD/CDMRP Breast Cancer Research Program Postdoctoral Fellowship, and DOD/CDMRP Visionary Postdoctoral Fellowship, a Young Investigator Award from the Arthritis National Research Foundation (ANRF), and most recently, he was awarded a $2 million CPRIT Scholar In Cancer Research Award from state of Texas.